What Philex Pharmaceuticals does

Philex Pharmaceuticals is a private multinational pharmaceutical manufacturer headquartered in Muscat, Sultanate of Oman, with a GMP-certified Solid Dosage Form Manufacturing Facility located in the Salalah Free Zone (SFZ) in southern Oman. The company manufactures and packages pharmaceuticals and biopharmaceuticals, with a stated portfolio of over 40 products spanning 14 therapeutic categories including cardiovascular, oncology, neurology, diabetology, anti-infectives, vaccines, pain management, respiratory, and urology. The product mix includes both small-molecule generics (e.g., Levetiracetam, Rosuvastatin, Tadalafil, Ondansetron) and more complex molecules such as monoclonal antibodies (Bevacizumab), immunomodulators (Lenalidomide), and vaccines (Hepatitis A — including a WHO-prequalified product with 60 million doses distributed — and Varicella). Manufacturing relies on multinational technology transfer partnerships that provide access to production know-how, enabling the company to position itself as a lower-cost supplier of affordable medicines.

The business model is anchored on B2B pharmaceutical product sales to government health ministries, healthcare providers, and pharmacy networks across the MENA and East Africa regions. Distribution occurs primarily through direct sales to healthcare providers, government tender participation (notably supply to the Directorate General of Medical Supplies — DGMS — under Oman's Ministry of Health), and pharmacy-network wholesale channels. Pricing is not publicly disclosed and is structured around tender pricing rather than transparent list pricing. GTM is enterprise field sales, with engagement at industry events such as the Oman International Pharmacy Congress & Exhibition, alongside a digital presence via corporate website, YouTube, and LinkedIn.

The company is privately held, with founder/management-led ownership under CEO Waseem Hamad and no disclosed institutional investors, parent company, or public-market listing. Operational maturity was demonstrated by receipt of the GCC GMP Certificate for its Solid Dosage Form Manufacturing Facility in March 2024, a key regulatory milestone enabling cross-GCC tender eligibility. Academic partnerships with Dhofar University (2023) and the National University of Science and Technology (2025) indicate investment in Oman's domestic pharmacy talent pipeline in alignment with Oman Vision 2040. Headcount is 51-100 employees, and no revenue, funding, or financial figures are publicly disclosed.

Name

Philex Pharmaceuticals

Legal name

Philex Pharmaceuticals

Website

https://philexpharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Philex Pharmaceuticals is a private Omani pharmaceutical manufacturer with a GCC GMP-certified facility in Salalah Free Zone, producing 40+ generics and complex molecules across 14 therapeutic areas and supplying government tenders, healthcare providers, and pharmacy networks across the MENA and East Africa regions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Biopharmaceutical products
• Vaccines production
• GMP certified facility

Headquarters

HQ city

New City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and sale of high-quality pharmaceuticals and biopharmaceutical products covering a wide range of therapeutic areas including cardiovascular, diabetes, oncology, neurology, anti-infectives, and vaccines. Products are sold to healthcare providers, pharmacies, and healthcare systems across the MENA and East Africa region.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Philex Pharmaceuticals manufactures and packages a broad portfolio of over 40 high-quality pharmaceuticals and biopharmaceutical products across multiple therapeutic areas including cardiovascular, diabetes, oncology, neurology, anti-infectives, vaccines, pain management, respiratory, and gastroenterology. Products are supplied to healthcare providers, pharmacies, and government health systems across the MENA region and East Africa via direct enterprise sales and government tenders.

Product overview

Philex Pharmaceuticals is a multinational pharmaceutical company headquartered in Oman that manufactures and distributes a broad portfolio of pharmaceutical products and vaccines. Their product portfolio includes: cardiovascular medications (anticoagulants like Flexan/Enoxaparin and Rivaroxaban, statins like Rosuvastatin, and fenofibrate); oncology treatments (Lenalidomide, Fulvestrant, Bevacizumab); anti-infectives (antibiotics like Levofloxacin, antifungals like Voriconazole and Caspofungin); neurology medications (Levetiracetam for epilepsy); gastroenterology products (Metoclopramide); respiratory treatments (Fluticasone nasal spray, Mometasone, Ambroxol); vaccines (Hepatitis A vaccines including HEALIVE Adult and Junior, Varicella vaccine); diabetes medications (Dapagliflozin, Sitagliptin, Vildagliptin, combination therapies like VELTEX MET and DEUX); urology products (Tadalafil for ED and BPH); pain management and anti-inflammatory medications (Etoricoxib, Lornoxicam, Paracetamol formulations including Panalex Infusion, Advance, and Extra); antiemetics (Ondansetron); antihistamines (Levocetirizine, Chlorpheniramine); and corticosteroids (Dexamethasone). Products are organized across therapeutic categories including Anti-allergic, Anti-bacterial, Anti-fungal, Anti-inflammatory, Cardiovascular, Diabetology, Gastroenterology, Neurology, Oncology, Pain Management, Respiratory, Urology, and Vaccines. The company holds GCC GMP certification for their Solid Dosage Form Manufacturing Facility.

Differentiator

Problem solved

Functional benefit

Brands

• Philex Pharma: Product brand name used on product pages for pharmaceutical products including dapagold, jentex, flason, broxal, chlomal, dexacure, metocol, caspen, levocin, and others
• Philex

Products and services

• Flexan (Enoxaparin) Anticoagulant medication for prevention and treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), available in 40mg, 60mg, and 80mg subcutaneous or intravascular injection forms. Targeted at healthcare providers and hospitals.
• Linatex (Lenalidomide) Immunomodulatory agent for treatment of Multiple Myeloma (used with dexamethasone) and lower-risk Myelodysplastic Syndromes associated with 5q deletion, available in 5mg, 10mg, and 25mg doses. Targeted at oncology treatment centers.
• FULVICURE (Fulvestrant) Hormonal therapy for metastatic or locally advanced breast cancer in postmenopausal women with estrogen receptor-positive, HER2-negative status, used as first or second-line treatment. Targeted at oncology specialists.
• AVATOMAB (Bevacizumab) Monoclonal antibody for treatment of metastatic colorectal cancer, advanced non-small cell lung cancer (NSCLC), and advanced renal cell carcinoma (RCC) in combination with chemotherapy. Targeted at oncology hospitals and treatment centers.
• Tiravex (Levetiracetam) Antiepileptic medication for treatment of partial-onset seizures, generalized tonic-clonic seizures, and myoclonic seizures in patients with epilepsy, available as 500mg and 1000mg oral tablets as well as 100mg/ml injectable form. Targeted at neurologists and epilepsy treatment centers.
• Ondex (Ondansetron) Antiemetic for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and postoperative nausea and vomiting (PONV), available in 8mg/4ml and 4mg/2ml injectable strengths. Targeted at oncology and surgical hospitals.
• VAZATIN (Rosuvastatin) Statin for treatment of hyperlipidemia and hypercholesterolemia, lowering LDL cholesterol, total cholesterol, and triglycerides while increasing HDL cholesterol, available in 10mg, 20mg, and 40mg strengths. Targeted at cardiovascular patients and primary care providers.
• RIXALTA (Rivaroxaban) Direct oral anticoagulant (DOAC) for treatment and prevention of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and stroke risk reduction in non-valvular atrial fibrillation, available in 15mg and 20mg oral doses. Targeted at cardiology and anticoagulation clinics.
• Lipoact (Fenofibrate) Fibrate for treatment of hyperlipidemia and hypertriglyceridemia, lowering LDL cholesterol and elevated triglycerides in patients at risk of pancreatitis, available in 200mg pellet form. Targeted at lipidology and primary care.
• VOREX (Voriconazole) Antifungal agent for treatment of invasive aspergillosis and candida infections including esophageal candidiasis, invasive candidiasis, and candidemia, available in 200mg formulation. Targeted at infectious disease and ICU specialists.
• CASPEN (Caspofungin) Echinocandin antifungal for treatment of invasive aspergillosis in patients intolerant to other antifungals, and candida infections including esophageal and invasive candidiasis, available in 50mg strength. Targeted at hospital infectious disease and ICU specialists.
• LEVOCIN (Levofloxacin) Fluoroquinolone antibiotic for treatment of respiratory tract infections including pneumonia and COPD exacerbations, urinary tract infections, and skin/soft tissue infections, available in 500mg strength. Targeted at hospitals and primary care.
• METOCOL (Metoclopramide) Prokinetic agent for treatment of nausea and vomiting caused by chemotherapy, surgery, or radiation, also used for GERD and gastroparesis, available in 10mg/2ml injectable form. Targeted at gastroenterology and oncology units.
• DEXACURE (Dexamethasone) Corticosteroid for treatment of inflammatory conditions like arthritis, bursitis, and colitis, and management of severe allergic reactions and anaphylaxis, available in 8mg/2ml injectable form. Targeted at hospitals and emergency care.
• CHLOMAL (Chlorpheniramine) Antihistamine for treatment of severe allergies including hay fever, allergic rhinitis, urticaria, and as adjunct to adrenaline in anaphylaxis, available in 10mg/1ml injectable form. Targeted at emergency and allergy care.
• BROXAL (Ambroxol) Mucolytic agent for treatment of respiratory conditions, available as elixir (15mg/5ml and 30mg/5ml) and 30mg tablet formulations. Targeted at respiratory and primary care.
• Levotex (Levocetirizine) Antihistamine for relief of allergic rhinitis (including persistent) and urticaria symptoms in adults and children 6 years and older, available in 5mg formulation. Targeted at allergy and primary care.
• FLASON (Fluticasone propionate spray) Nasal corticosteroid spray for temporary relief of hay fever and upper respiratory allergy symptoms including nasal congestion, itchy/watery eyes, runny nose, and sneezing, available in 50mcg spray formulation. Targeted at allergy and ENT specialists.
• Motex (Mometasone Furoate spray) Nasal corticosteroid spray for treatment of seasonal or perennial allergic rhinitis symptoms, acute rhinosinusitis, and nasal polyps, available in 50mcg spray formulation. Targeted at allergy and ENT specialists.
• Sky Varicella (Varicella virus vaccine) Live attenuated varicella vaccine for prevention of varicella infection in children aged 12 months to 12 years, administered as single 0.5mL subcutaneous dose. Targeted at pediatric immunization programs and government health ministries.
• HEALIVE Adult (Hepatitis A Vaccine) WHO-prequalified inactivated hepatitis A vaccine (Human Diploid cell) for adult use, with over 17 years of market experience and 60 million doses administered worldwide. Targeted at government immunization programs and adult vaccination.
• HEALIVE Junior (Hepatitis A Vaccine) WHO-prequalified inactivated hepatitis A vaccine (Human Diploid cell) for pediatric use, exported to 16 countries and UN Market (PAHO and UNICEF). Targeted at pediatric immunization programs.
• DAPAGOLD (Dapagliflozin) SGLT2 inhibitor for control of Type 2 Diabetes Mellitus in adult patients above 18 years, acting as antihyperglycemic agent, available in 10mg strength. Targeted at diabetology and primary care.
• JENTEX (Sitagliptin) DPP-4 inhibitor oral medication for management of Type 2 Diabetes Mellitus, improving glycemic control by increasing insulin release and decreasing hepatic glucose production, available in 50mg and 100mg strengths. Targeted at diabetology.
• VELTEX (Vildagliptin)

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and moderate.

• National University of Science and Technology - College of PharmacycoreStrategic or Co-development Partner · 22 June 2025Philex Pharmaceuticals signed a Memorandum of Understanding (MoU) with the College of Pharmacy at the National University of Science and Technology to strengthen cooperation in student internships, hands-on training programs, short courses, and development of academic curricula aligned with pharmaceutical industry needs. The MoU was signed by Dr. Waseem Hamad, CEO of Philex Pharmaceuticals, in the presence of senior officials from both institutions.
• Dhofar UniversitycoreStrategic or Co-development Partner · 29 November 2023Collaboration between Philex Pharmaceuticals and Dhofar University aimed at empowering students and fostering experiential learning in alignment with Oman Vision 2040, which emphasizes development of a knowledge-based economy and empowerment of youth. The partnership provides students with practical experience and exposure to industry best practices.
• Multinational Partners (unspecified)moderateTechnology or IntegrationPhilex Pharmaceuticals partners with multinational entities for innovative drug development at affordable prices and technology transfer. The company is committed to finding partnerships that improve patient outcomes and serve society through access to innovative medicines.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered multinational pharmaceutical manufacturer with a broad generics portfolio across MENA. Directly comparable to Philex as a regional manufacturer targeting Gulf and African markets with cardiovascular, anti-infective, and diabetes portfolios.
• Hikma Pharmaceuticals: Jordanian-origin multinational with strong MENA and emerging markets presence, manufacturing generics, branded, and injectable pharmaceuticals. Closest large-cap analog to Philex's regional-generics-plus-injectables strategy.
• Oman Pharmaceutical Products (OPP): Domestic Omani pharmaceutical manufacturer producing generics for the local market and selected export. Directly comparable as a fellow Omani-headquartered pharma producer competing for the same DGMS tenders and regional distribution.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-based pharmaceutical manufacturer supplying generics and specialty products across the GCC and wider MENA region. Comparable as a GCC-anchored manufacturer competing in similar government tender channels with multi-therapeutic portfolios.

Broad incumbents

• Dr. Reddy's Laboratories: Indian pharmaceutical company with significant generics, biosimilars, and API operations, including emerging markets focus. Comparable for its biosimilar (bevacizumab, rituximab) and specialty injectable capabilities that overlap with Philex's portfolio direction.
• Cipla: Indian multinational with deep MENA and emerging markets presence across respiratory, cardiovascular, and anti-infectives. Comparable as a broad-portfolio incumbent that regional manufacturers like Philex must displace or partner with.
• Aspen Pharmacare: South African-headquartered multinational with strong presence across Africa and emerging markets in generics and specialty pharmaceuticals. Comparable for its emerging-market commercial model and tender-heavy go-to-market approach.
• Zydus Cadila (Cadila Healthcare): Indian multinational with biosimilars, generics, and specialty pharma operations, including emerging market exports. Comparable for its biosimilar pipeline and emerging market commercialization model relevant to Philex's growth trajectory.
• Aurobindo Pharma: Large Indian generics manufacturer with established MENA and Africa distribution and API manufacturing scale. Comparable as a cost-competitive generics exporter that frequently competes with regional manufacturers like Philex on tender pricing.

Regional players

• Saudi Pharmaceutical Industries & Medical Appliances Corp (Spimaco Addwaeih): Saudi manufacturer producing generics, injectables, and medical supplies primarily serving Saudi Arabia and select Gulf states. Comparable regional manufacturer competing in similar therapeutic categories and government procurement channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@philexpharmaceuticals9277
• LinkedInlinkedin.com/company/philex-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Philex Pharmaceuticals